Improving Medical Device Regulation: The United States and Europe in Perspective

被引:99
作者
Sorenson, Corinna [1 ]
Drummond, Michael [1 ,2 ]
机构
[1] Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England
[2] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England
关键词
medical devices; regulation; health care reform; comparative studies; PREMARKET APPROVAL; POSTMARKETING SURVEILLANCE; CARDIOVASCULAR DEVICE; FDA; INCLUSION; RECALLS; RISK;
D O I
10.1111/1468-0009.12043
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
ContextRecent debates and events have brought into question the effectiveness of existing regulatory frameworks for medical devices in the United States and Europe to ensure their performance, safety, and quality. This article provides a comparative analysis of medical device regulation in the two jurisdictions, explores current reforms to improve the existing systems, and discusses additional actions that should be considered to fully meet this aim. Medical device regulation must be improved to safeguard public health and ensure that high-quality and effective technologies reach patients. MethodsWe explored and analyzed medical device regulatory systems in the United States and Europe in accordance with the available gray and peer-reviewed literature and legislative documents. FindingsThe two regulatory systems differ in their mandate and orientation, organization, pre- and postmarket evidence requirements, and transparency of process. Despite these differences, both jurisdictions face similar challenges for ensuring that only safe and effective devices reach the market, monitoring real-world use, and exchanging pertinent information on devices with key users such as clinicians and patients. To address these issues, reforms have recently been introduced or debated in the United States and Europe that are principally focused on strengthening regulatory processes, enhancing postmarket regulation through more robust surveillance systems, and improving the traceability and monitoring of devices. Some changes in premarket requirements for devices are being considered. ConclusionsAlthough the current reforms address some of the outstanding challenges in device regulation, additional steps are needed to improve existing policy. We examine a number of actions to be considered, such as requiring high-quality evidence of benefit for medium- and high-risk devices; moving toward greater centralization and coordination of regulatory approval in Europe; creating links between device identifier systems and existing data collection tools, such as electronic health records; and fostering increased and more effective use of registries to ensure safe postmarket use of new and existing devices.
引用
收藏
页码:114 / 150
页数:37
相关论文
共 44 条
  • [21] Commentary: Use of registries to investigate the past and develop the future
    James, Stefan
    Daubert, Jean-Claude
    Van de Werf, Frans
    [J]. BRITISH MEDICAL JOURNAL, 2011, 342 : d2826
  • [22] Regulation of Medical Devices in the United States and European Union
    Kramer, Daniel B.
    Xu, Shuai
    Kesselheim, Aaron S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) : 848 - 855
  • [23] Kruger KH, 2012, BUSINESS OF HEALTHCARE INNOVATION, 2ND EDITION, P376
  • [24] Ladin Z., 2010, FDA REV PATTERNS DE
  • [25] Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden
    Lagerqvist, Bo
    James, Stefan K.
    Stenestrand, Ulf
    Lindback, Johan
    Nilsson, Tage
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (10) : 1009 - 1019
  • [26] Post-marketing Surveillance Why the FDA can't protect the public
    Lenzer, Jeanne
    Brownlee, Shannon
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2010, 341
  • [27] Postmarketing surveillance of medical devices using Medicare claims
    Malenka, DJ
    Kaplan, AV
    Sharp, SM
    Wennberg, JE
    [J]. HEALTH AFFAIRS, 2005, 24 (04) : 928 - 937
  • [28] Meier B., 2013, NY TIMES
  • [29] Miller R., 2009, MEDSCAPE
  • [30] Miller R., 2011, Medscape